Group 1 - The core viewpoint of the news highlights the recent performance and market position of Berry Genomics, noting a significant stock price increase and a low market-to-book ratio [1] - On May 13, Berry Genomics closed at 13.96 yuan, up 10.01%, with a market capitalization of 4.935 billion yuan and a price-to-book ratio of 2.96, marking a new low in 31 days [1] - The company experienced a net inflow of 137.79 million yuan in main funds on May 13, with a total inflow of 102.66 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, offering related equipment and reagent sales [1] - The company provides comprehensive solutions through "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The latest financial report for Q1 2025 shows the company achieved revenue of 218 million yuan, a year-on-year decrease of 22.08%, with a net loss of approximately 6.46 million yuan, reflecting a year-on-year decline of 178.47% and a gross profit margin of 49.48% [1] Group 3 - In comparison to industry averages, Berry Genomics has a TTM PE ratio of -23.83 and a static PE ratio of -25.65, with a market capitalization of 4.935 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 50.06 and the static PE at 45.92, indicating that Berry Genomics is underperforming relative to its peers [2] - The industry median market capitalization is 4.795 billion yuan, suggesting that Berry Genomics is positioned within a competitive landscape [2]

5月8日，贝瑞基因今日收盘12.97元，上涨1.41%，最新市净率2.75，创13天以来新低，总市值45.85亿 元。 成都市贝瑞和康基因技术股份有限公司主营业务为以高通量测序技术为基础的基因检测服务和基因检测 相关的设备、试剂销售。公司主要产品为基础科研服务、医学检测服务、试剂及仪器。公司是少数通 过"产品+服务"的综合方案为各级医院、第三方医学实验室等医疗机构提供医学产品及服务的公司之 一，凭借NIPT项目的先发优势，不断多元化基因检测服务项目并适时进行产品化，凭借在临床应用需 求的洞察力和在临床进行商业推广的成功经验，确立了公司在遗传学领域的领导地位。公司自主研发 的、具有万级技术分辨率的cSMART液态活检技术已获得国内外专利，凭借该技术优势，确立了公司在 肿瘤学领域的领先地位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.18亿元，同比-22.08%；净利润-6462206.12 元，同比-178.47%，销售毛利率49.48%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)19贝瑞基因-22.14-23.832.7545.85亿行业平均 49.2047.654.59104.8 ...

4月29日，贝瑞基因今日收盘11.93元，上涨1.19%，最新市净率2.53，总市值42.18亿元。 股东方面，截至2025年3月31日，贝瑞基因股东户数63808户，较上次增加19482户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21贝瑞基因-20.36-21.922.5342.18亿行业平均 47.7444.884.40101.07亿行业中值36.1535.662.2846.25亿1硕世生物-1832.01-1832.011.1336.67亿2天益医 疗-1617.63-2770.811.7320.61亿3澳华内镜-556.10278.924.4658.61亿4诺唯赞-416.32-492.392.2889.09亿5博 晖创新-319.59507.143.4146.89亿6爱朋医疗-296.17225.003.5724.30亿7奥精医疗-114.89-168.391.5221.32亿 8睿昂基因-90.84-74.581.2911.76亿9康泰医学-80.95-68.392.8953.28亿10中红医疗-66.61-53.130.84 ...

股东方面，截至2025年3月31日，诺禾致源股东户数9593户，较上次增加2709户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21诺禾致源27.5328.452.2155.98亿行业平均 45.0541.013.36141.40亿行业中值46.9735.682.4248.61亿1普瑞眼科-185.6423.202.8062.17亿2何氏眼 科-146.8145.011.4828.60亿3光正眼科-92.66220.167.4720.38亿4迪安诊断-92.2327.771.2185.37亿5南华生 物-81.46-107.1912.1430.20亿6创新医疗-42.79-42.792.2640.20亿7国际医学-32.95-32.033.23117.99亿8嘉和 美康-26.93-26.932.2640.40亿9皓宸医疗-22.04-22.704.7821.42亿10美迪西-11.99-11.991.6137.86亿11和元生 物-10.96-10.961.9135.63亿 4月16日，诺禾致源今日收盘13.45元，下跌1.54%，滚动市 ...